Fibrotic diseases encompass numerous systemic and organ-specific disorders characterized by the development and persistence of myofibroblasts. Peter Berger and colleagues published data in Experimental Cell Research demonstrating that i ncrease of cGMP by sGC stimulators/activators inhibits and reverts myofibroblast differentiation of dermal and prostatic stromal cells indicating that enhancement of cGMP/NO-signaling is a promising strategy for treatment of fibrosis.